Sign in or register today for access to this and other blogs and discussions.
Richard Lehman reflects on a European Medicines Agency data transparency workshop held to discuss ideas for executing the EMA's new policy of allowing access to all data submitted for drug licensing. Do you see this as a harbinger of change for the FDA?
CardioExchange is an online community hosted by the New England Journal of Medicine and Journal Watch and dedicated to improving cardiac patient care. Membership is free for medical professionals.